We are live on
!
Find out more
RI
RTW Investments Portfolio holdings
AUM
$11.7B
1-Year Est. Return
174.13%
This Fund
S&P 500
This Quarter
Est. Return
+27.09%
1 Year Est. Return
+174.13%
3 Year Est. Return
+466.81%
5 Year Est. Return
+622.69%
10 Year Est. Return
+19,772.83%
AUM
$11.7B
AUM Growth
+$1.66B
(+17%)
Cap. Flow
-$50.3M
Cap. Flow
% of AUM
-0.43%
Top 10 Holdings %
Top 10 Hldgs %
47.72%
Holding
97
New
9
Increased
26
Reduced
8
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
KLRA
Kailera Therapeutics
KLRA
|
+$237M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
+$103M |
| 3 |
CG Oncology
CGON
|
+$100M |
| 4 |
ORKA
Oruka Therapeutics
ORKA
|
+$72M |
| 5 |
Structure Therapeutics
GPCR
|
+$71.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apogee Therapeutics
APGE
|
+$234M |
| 2 |
APLS
Apellis Pharmaceuticals
APLS
|
+$148M |
| 3 |
Cogent Biosciences
COGT
|
+$110M |
| 4 |
Intuitive Surgical
ISRG
|
+$101M |
| 5 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$81.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.93% |
| 2 | Financials | 0.07% |
| 3 | Miscellaneous | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Capricor Therapeutics
CAPR
$558M
| $6.02M | 0.05% |
250,000
| – | – |
|
|
KLRS
77
Kalaris Therapeutics
KLRS
$95.9M
| $5.29M | 0.05% |
1,300,000
| – | – |
|
|
ABVX
78
Abivax
ABVX
$9.89B
| $3.52M | 0.03% |
+26,400
| New | +$2.99M |
|
79
Avalo Therapeutics
AVTX
$1.05B
| $3.23M | 0.03% |
175,000
-681,962
| -80% | -$10.8M |
|
|
MDLN
80
Medline Inc
MDLN
$31B
| $2.76M | 0.02% |
70,000
| – | – |
|
81
Disc Medicine
IRON
$3.07B
| $2.19M | 0.02% |
30,000
| – | – |
|
|
IMA
82
ImageneBio Inc
IMA
$60.6M
| $1.97M | 0.02% |
334,445
| – | – |
|
83
Exagen
XGN
$179M
| $907K | 0.01% |
195,000
-200,231
| -51% | -$754K |
|
84
Rocket Pharmaceuticals Warrant
RCKTW
$74.7K
| $1.19K | ﹤0.01% |
350,000
| – | – |
|
|
85
Apogee Therapeutics
APGE
$10.2B
| – | – |
-2,782,097
| Closed | -$234M |
|
|
APLS
86
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-3,685,045
| Closed | -$148M |
|
87
Arrowhead Research
ARWR
$12B
| – | – |
-585,682
| Closed | -$36.7M |
|
|
JBIO
88
Jade Biosciences
JBIO
$1.33B
| – | – |
-573,205
| Closed | -$8.05M |
|
89
Compass Therapeutics
CMPX
$432M
| – | – |
-4,186,599
| Closed | -$22.1M |
|
|
CNTA
90
DELISTED
Centessa Pharmaceuticals
CNTA
| – | – |
-2,054,175
| Closed | -$81.6M |
|
91
Crinetics Pharmaceuticals
CRNX
$9B
| – | – |
-1,451,326
| Closed | -$52.7M |
|
92
Fulgent Genetics
FLGT
$540M
| – | – |
-1,289,000
| Closed | -$20.5M |
|
|
93
Intuitive Surgical
ISRG
$132B
| – | – |
-220,000
| Closed | -$101M |
|
|
IVA
94
Inventiva
IVA
$1.11B
| – | – |
-1,298,702
| Closed | -$7.21M |
|
95
Stryker
SYK
$127B
| – | – |
-100,000
| Closed | -$32.9M |
|
|
WAY
96
Waystar Holding Corp
WAY
$5.03B
| – | – |
-1,630,000
| Closed | -$39.3M |
|
|
OMDA
97
Omada Health Inc
OMDA
$1.45B
| – | – |
-200,000
| Closed | -$2.51M |
|
Similar funds
CIM
MIF
QC
UE
CIA
FPAS
CCMT
RTW Investments's Q2 2026 Portfolio in Review
As of Q2 2026, RTW Investments held 97 positions worth $11.7B, up 17% from $10B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
RTW Investments's Q2 2026 filing shows 9 new, 26 increased, 8 reduced and 13 closed positions. Its largest new stake was Kailera Therapeutics: 10,776,820 shares worth $237M. The largest sale was Apogee Therapeutics, an estimated $234M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials and Miscellaneous.
- RTW Investments's largest Q2 2026 buy was Kailera Therapeutics: 10,776,820 shares worth $237M.
- RTW Investments added most to Ultragenyx Pharmaceutical in Q2 2026, an estimated $103M increase.
- RTW Investments's biggest Q2 2026 reduction was Cogent Biosciences, cutting an estimated $110M.
- RTW Investments fully exited Apogee Therapeutics in Q2 2026, selling an estimated $234M.
- RTW Investments's ten largest holdings make up 48% of its $11.7B portfolio in Q2 2026.
- RTW Investments opened 9 new positions and closed 13 in Q2 2026.
- RTW Investments's portfolio value rose 17% quarter-over-quarter to $11.7B.
Based on RTW Investments's 13F filing for Q2 2026, filed 14 Aug 2026.